Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

ClinicalTrials.gov ID: NCT00045734

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00045734. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth

Study identification

NCT ID
NCT00045734
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
23 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2003 (Type not available)
Primary completion
Dec 2009 (Actual)
Completion
Dec 2009 (Actual)
Last update posted
May 15, 2017

2003 – 2009

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
University of California Los Angeles Los Angeles California 90095 —
University of California San Francisco San Francisco California 94115 —
National Cancer Institute Neuro-Oncology Branch Bethesda Maryland 20814 —
Dana Farber Cancer Institute Boston Massachusetts 02115 —
Memorial Sloan-Kettering Cancer Center New York New York 10021 —
University of Texas Southwestern Medical Center Dallas Texas 75235 —
University of Wisconsin Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00045734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 15, 2017 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.